Eczema (Atopic Dermatitis)
main-banner
Eczema (Atopic Dermatitis)
18569 Enrolling

Clinical Trial for Atopic Dermatitis (13-17 Months)


Treatment: Injection Age: 18 Years


Seeking adults aged 18 years to 70 years with a clinical diagnosis of atopic dermatitis (AD), with AD-involved body surface area (BSA) ≥ 10% at (roughly the size of 10 palm prints or more).Inclusion criteria include having moderate-to-severe AD.

Participants will receive either treatment via a subcutaneous injection (SC) or placebo  Study treatment and study-related assessments will be provided at no cost. Reimbursement for study-related expenses may be provided.


Participating Locations

Participating Experts

Dr. Maryam Shayesteh Alam

Dermatologist

Dr. Charles Lynde

Dermatologist

Dr. Marni Wiseman

Dermatologist

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: June 09, 2024

Official Title

A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52 Week Study to Evaluate the Efficacy and Safety of LY3454738 in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

ClinicalTrials.gov ID

NCT05911841

Sponsor

Eli Lilly and Company

Study Description

  • Brief Summary:

    The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).

  • Condition or Disease:

    Atopic Dermatitis

  • Intervention/Treatment:

    Drug: LY3454738
    Drug: LY3454738
    Drug: LY3454738
    Drug: Placebo
  • Phase:

    Phase 2

  • Ages Eligible for Study:

    18 Years and 70 Years (Adult)

  • Sexes Eligible for Study:

    All

Inclusion Criteria:

Are candidates for systemic therapy.

ISA specific:

Have moderate-to-severe AD, defined as meeting all of the following criteria, at the first dosing visit:

EASI score greater than or equal to (≥)16
vIGA-AD score ≥3, and
≥10% of BSA involvement (per EASI BSA).
Have applied at least 1 emollient every day for at least 2 weeks before the day of the first dose of study intervention in this ISA and agree to daily use of at least 1 emollient continuously throughout the study.

Exclusion Criteria:

ISA specific:

Have, in the screening period, any of the skin conditions, infections, or medical conditions listed under master IMMB.
Are currently being treated with topical or systemic therapy
Recent treatment with experimental (biologics and/or small molecules) – doesn’t apply for subset of participants who must have been exposed to biologics and/or small molecules.


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Eczema (Atopic Dermatitis)

Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials
Skip to content